Urine test study for second bladder surgery
Part of Cancer, Genetic & congenital, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial compares the need for a second surgery for people with early-stage bladder cancer. It uses a simple urine test to see if the test can help decide whether a second operation is necessary, which could save some patients from an extra procedure.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with non-muscle-invasive bladder cancer (cancer that hasn't spread into the deep muscle of the bladder).
- You have already had a first surgery to remove the tumor (transurethral resection) and your doctor plans a second surgery soon.
- Your first surgery was incomplete (tumor too large or bleeding risk), or didn't have muscle in the sample, or showed T1 stage (slightly deeper layer) or high-grade (G3) tumor (more aggressive cells).
- You can give a urine sample (about 100 ml) between 1 week and 6 weeks after your first surgery, but before the second surgery.
- You are 18 years old or older.
- You do not have any other type of cancer starting in the urinary tract (like prostate or kidney cancer), and you have never been diagnosed with muscle-invasive bladder cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether a second bladder surgery is still needed for people with high-risk bladder cancer who had a negative urine test after their first surgery.
This trial checks whether a bladder scan and score (VI-RADS from MRI) can help doctors choose the right way to do a second look surgery for non-muscle-invasive bladder cancer. The goal is to reduce the chance of needing extra (“secondary”) resections while still catching important disease early.
This trial tests STM-416, given around the time you have surgery to remove recurring bladder tumors, to see if it can reduce the chance the cancer comes back. It is for people with high-risk early bladder cancer (non–muscle-invasive) who have already had standard treatment and now need another TURBT.
This Phase 2 study tests whether urine tests can help monitor “non-muscle-invasive” bladder cancer without doing as many invasive bladder scopes (cystoscopies). If you qualify, you may be able to replace some scope visits with urine sample testing while still keeping close watch for cancer coming back.
This study is collecting blood, urine, and tissue samples from people with high-risk non-muscle invasive bladder cancer to help develop better tests for tracking the disease. By participating, you might help improve future monitoring and treatment decisions.
This trial is testing whether a urine test for tumor DNA/RNA can help guide the decision for a second surgery in people with high-risk, non-muscle-invasive bladder cancer. It aims to see if the urine test can predict who needs the second surgery, potentially avoiding unnecessary procedures.
Hear when a new Non Muscle Invasive Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.